Navigation Links
The Largest Pharma Fraud Whistleblower Case in U.S. History Totaling $1.4 Billion
Date:1/15/2009

Philadelphia Attorney Stephen Sheller's Whistleblower Clients Help Government Recover $1.4 Billion Record Settlement and Criminal Fine in Eli Lilly & Company Zyprexa(R) Marketing Case

Lead Attorney Filed Complaint in 2003 Representing Six Whistleblowers

PHILADELPHIA, Jan. 15 /PRNewswire-USNewswire/ -- Pharmaceutical giant Eli Lilly & Company ("Lilly") will pay federal and state governments more than $1.4 billion to remedy a wide-ranging, off-label marketing scheme for its prescription drug, Zyprexa(R). This settlement is the largest qui tam settlement in the history of the False Claims Act.

Stephen A. Sheller, a well-known mass tort and class action lawyer from Philadelphia, filed the first Complaint in the case in February 2003, bringing the off-label drug allegations to the government under seal as required by law. Today, after six years, the Department of Justice settled with Lilly the allegations that six former Lilly drug marketing representative whistleblowers brought to Sheller.

Lilly will pay more than $1.4 billion for its illegal off-label marketing of the antipsychotic drug, the U.S. Attorney's Office for the Eastern District of Pennsylvania announced. Zyprexa is Lilly's top-selling drug with worldwide sales of nearly $40 billion since its approval in 1996.

In today's settlement, Lilly will pay $800 million in civil penalties and plead guilty to criminal charges, paying an additional $600 million fine. The six whistleblowers who brought the Complaint against the drug company will share in approximately 18 percent of the federal and qualifying states' recoveries, Sheller said.

Related complaints filed by other law firms in 2005, 2006 and 2007 were ultimately consolidated into Sheller's first-filed Complaint.

"The reason the settlement and fine are record-breaking is because Eli Lilly perpetrated an outrageous fraud on the American government and taxpayers" said Sheller.

The whistleblowers represented by Sheller, two with 27 or more years' service at Lilly, expressed concern through proper channels about Lilly's improper marketing practices. All six whistleblowers were eventually fired or forced to resign. One sales representative, who also is a pharmacist, contacted the company hotline regarding unethical sales practices but received no response, according to the Complaint.

Zyprexa is approved by the U.S. Food and Drug Administration ("FDA") for very limited conditions - schizophrenia and a specific type of bipolar disorder. Under FDA rules, prescription drug manufacturers and marketers may only promote their products for approved uses.

To boost sales, Eli Lilly marketed Zyprexa for numerous off-label uses including Alzheimer's, depression and dementia according to Sheller's Complaint.

Eli Lilly's off-label sales strategies were very effective. The government's investigation found that a substantial amount of Zyprexa sales were for off-label uses, particularly in children and the elderly.

For years, Lilly has been accused of influencing doctors to prescribe Zyprexa to treat disruptive children and tranquilize nursing home patients. The FDA has not approved the drug for children or the elderly and the side effects of the drug are significant: inducing heart failure and pneumonia in the elderly and increasing the risk of significant weight gain and diabetes in children.

According to the Sheller Complaint, some of the tactics used by Eli Lilly to push Zyprexa sales beyond the drug's approved use were:

  • During off-label lectures and audio conferences for physicians Lilly sales people posed as persons in the audience who were interested in Zyprexa's expanded use and asked "planted questions;"

  • While knowing the significant risk for weight gain posed by Zyprexa, Lilly minimized the connection between Zyprexa and weight gain in a widely disseminated videotape called "The Myth of Diabetes" which used "allegedly scientific studies of questionable integrity as well as the haphazard reporting of adverse events;"

  • Providing evidence that, in the summer of 2003, Lilly management ordered the destruction of sales literature with misleading information, "core sales aids, flip charts and acetates;" and

  • Promoting the sublingual version of Zyprexa, called "Zydis," by claiming that it did not have the same weight-gain effects as Zyprexa.

Federal and state False Claims Acts allow private individuals to sue companies that knowingly defraud national or state governments. They also protect whistleblowers from demotion, suspension, harassment and discrimination for cooperating with the investigation of their employer.

"I applaud the courage of these whistleblowers. They came forth at personal and professional risk to protect the American people and expose corporate fraud," Sheller said.

Sheller also lauded the cooperation among federal prosecutors, investigators, the National Association of Medicaid Fraud Control Units and whistleblowers' attorneys that led to today's settlement. "The collaborative efforts we all took to bring this case to a conclusion is an affirmation of how experienced whistleblower lawyers can work with authorities to reach a satisfactory conclusion," Sheller said.

Acting United States Attorney Laurie Magid and Civil Division Assistant U.S. Attorneys Joseph Trautwein, Virginia Gibson, Peg Hutchison and Kathy Votaw of the Eastern District of Pennsylvania managed and oversaw the investigation. The criminal case was managed by Linda Hoffa, Criminal Division Chief. Sheller was effusive in his praise for the government attorneys, "The U.S. Attorneys' Office in Philadelphia did exemplary work on this case. As a citizen, I was thrilled to see such an effective team."

Joining Sheller in the case are attorneys Gary Farmer, Esq. of Rothstein Rosenfeldt Adler in Fort Lauderdale, Florida and Philadelphia attorney Michael Mustokoff, Esq. of Duane Morris.

The settlement is detailed in a 37-page Settlement Agreement, as well as in a Corporate Integrity Agreement executed by Lilly and the Office of Inspector General of the Department of Health and Human Services.

United States of America ex rel Robert Rudolph, et al. v. Eli Lilly & Company, Civil Action No. 03-943 (E.D. Pa.)

About Sheller, P.C.

Sheller P.C. (http://www.Sheller.com) is among the preeminent plaintiff and qui tam whistleblower law firms in the United States. Stephen A. Sheller, Esq., Managing Partner, has been an effective advocate for victims for nearly three decades. Sheller has litigated groundbreaking cases ranging from premises liability and automobile litigation to defective drugs, products liability and whistleblower lawsuits. The firm also practices in complex mass tort and commercial litigation involving business disputes and consumer fraud. Mr. Sheller began the Palm Beach County, Florida litigation involving the 2000 U.S. Presidential election and the "butterfly ballots" which launched him into national media prominence as a lead attorney challenging the voting count. Sheller frequently appears on "The American Law Journal," the television talk program on the law that airs on The Comcast Network.


'/>"/>
SOURCE Sheller, P.C.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. National Association of Subrogation Professionals (NASP), the Largest Insurance Subrogation Association in the World - Announced Today that Leslie Wiernik has Joined the Organization as Director of Education
2. Work time is the largest influence to the duration of a persons sleep
3. One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High
4. Texas Largest Physician Carrier Announces 5th Successive Rate Cut on Anniversary of Lawsuit Reform
5. A Place for Mom, Nations Largest Senior Care Referral Service, Fills a Gap in Employee Benefits
6. AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks with ADHD Medications
7. Worlds Largest Exhibit of Princess Dianas Dresses Hosted by Appleton Museum
8. Largest Privately-Owned Veterinary Practice in the World, Banfield, the Pet Hospital(R), Appoints New Chief Executive Officer
9. Plenary lectures announced for worlds largest osteoporosis congress
10. The Integrated Benefits Institute Offers Largest Benchmarking Database in U.S. Spanning Disability and Workers Compensation Programs
11. Nations Largest Dialysis Patient Organization Recognizes the Achievements of Patients and Leaders in Kidney Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... The Aesthetic Channel has recently highlighted ... has come up with a proprietary technique that he calls the AuraLyft ... dropped. For all ages, patients can expect to look refreshed, rejuvenated, and revitalized. ...
(Date:6/23/2017)... ... June 23, 2017 , ... PureLife Dental is pleased to announce that California ... members. As part of the amalgam separator endorsement, all CDA members may purchase an ... off the retail value. This partnership between PureLife and CDA is especially timely as ...
(Date:6/23/2017)... ... June 23, 2017 , ... Jusino Insurance ... to communities in the greater Chicago metropolitan area, is embarking on a charity ... youth in Chicago. , Founded in 1897, Hephzibah Children’s Association is one of ...
(Date:6/22/2017)... Rosa, CA (PRWEB) , ... June 22, 2017 , ... ... been named as a Top Doctor for 2017. Each year, research and information firm, ... country. First winning the title in 2015, this marks the 3rd time that ...
(Date:6/22/2017)... ... 2017 , ... The VA Maryland Health Care System has ... the Baltimore VA Medical Center, a division of the VA Maryland Health Care ... promote waste reduction and promote recycling. Also, Practice Greenhealth has recognized the ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... HAMPTON, Va. , June 14, 2017  ivWatch ... safety and effectiveness of intravenous (IV) therapy, is pleased ... in the category of Nonsurgical Hospital Supplies and Equipment ... premier awards program for the medtech industry. The award ... at the Jacob K. Javits Center in ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company ... from three Phase 3 studies of galcanezumab, an investigational ... including late-breaking data on several key secondary endpoints for ... results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will ... annual scientific meeting in Boston . ...
(Date:6/8/2017)... 2017   Responding to Heath Ledger,s father,s ... of singer Chris Cornell in May, the mental ... a free online psychiatric drug side effects ... about psychotropic drug risks. The father of ... an accidental overdose, has called for tighter rules on prescription ...
Breaking Medicine Technology: